ClinicalTrials.gg
Not yet recruitingNCT07933666Updated Nov 12, 2026

A Phase I of FXS0260 in Advanced Solid Tumor

A Phase 1 interventional study of FXS0260 in Solid Tumor Refractory to Conventional Treatment, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a Phase I, single-arm, open-label, dose-escalation and dose-expansion clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of FXS0260 in participants with advanced solid tumors.

Read the detailed description

The study consists of two parts: Phase Ia dose escalation and Phase Ib dose expansion.

Phase Ia is an open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of FXS0260 in participants with advanced solid tumors. Approximately 20 participants are expected to be enrolled.

Dose escalation will be conducted using an accelerated titration design combined with the Bayesian Optimal Interval (BOIN) design. The prespecified dose levels are 5 mg BID, 20 mg BID, 60 mg BID, 120 mg BID, and 180 mg BID.

The accelerated titration design will be applied to the 5 mg BID and 20 mg BID dose cohorts, while the BOIN design will be implemented starting from the 60 mg BID dose cohort.Only one participant will initially be enrolled in each of the 5 mg BID and 20 mg BID dose cohorts. If a dose-limiting toxicity (DLT) or a Grade ≥2 study drug-related adverse event (AE) occurs during the DLT observation period, the current dose cohort will transition to the BOIN design, with enrollment expanded to a total of 3 participants.

Participants will receive a single oral dose of FXS0260 under fasting conditions during the single-dose administration period. The DLT observation period will be 24 days following the first dose (including the single-dose administration period and Cycle 1). Participants will subsequently enter Cycle 2 and subsequent cycles for multiple-dose treatment.Study treatment will continue until disease progression, death, unacceptable toxicity, withdrawal of informed consent, or other reasons requiring discontinuation of study treatment, whichever occurs first.

Phase Ib is an open-label, dose-expansion study that will enroll eligible participants with advanced solid tumors. The sample size will be determined based on the results of the Phase Ia dose-escalation study.This phase aims to further evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of FXS0260 at the recommended dose level(s) for expansion (1-2 dose cohorts).

02

Conditions studied

  • Solid Tumor Refractory to Conventional Treatment
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged ≥18 years;
  2. Fully understand the requirements of this study and voluntarily sign the written form;
  3. Participants with histologically/ diagnosed advanced solid tumors who have received standard treatment before participating in this study and for whom standard treatment has failed or no standard treatment is available; priority will be given to participants with advanced endometrial cancer, advanced ovarian cancer, advanced colorectal cancer, advanced gastric cancer, and advanced breast cancer;
  4. At least one according to the (RECIST) v1.1 (lesions previously treated with radiotherapy cannot be considered target lesions unless obvious progression has occurred);
  5. performance status score of 0-1;
  6. ≥12 weeks;
  7. Adequate organ and bone marrow function:

    Hematology (no red blood cell or transfusion or growth factor infusion within 7 days before the first administration of FXS0260):

    • ≥95 g/L;
    • ≥1.5 × 10⁹/L (≥1500 cells/mm³);
    • Platelet count ≥100 × 10⁹/L (≥100,000 cells/mm³);

    Coagulation:

    • and APTT ≤1.5 × ;
    • INR ≤1.5 × ULN.

    Liver:

    • Total ≤1.5 × ULN (if the participant is diagnosed with Gilbert's syndrome, total bilirubin ≤3 × ULN and direct bilirubin ≤1.5 × ULN are allowed);
    • /AST ≤3 × ULN (≤5 × ULN in the presence of liver ).

    Kidney:

    • ≥60 mL/min. Creatinine clearance will be calculated using the Cockcroft-Gault formula.
  8. Female participants of must have a negative serum pregnancy test within 7 days before the first administration of the study drug; eligible participants of (male and female) must agree to use reliable methods (hormonal or barrier methods or abstinence, etc.) together with their partners during the study and for at least 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are still within the of previous antitumor treatment drugs before the first administration of FXS0260 (4 weeks or 5 half-lives after the last dose, whichever is shorter);
  2. Participants who have previously received PKMYT1 inhibitors;
  3. Participants who have participated in a clinical study within 4 weeks before the first administration of FXS0260;
  4. Participants with a history of allergy to any known component or analogue of FXS0260;
  5. Participants who require strong inhibitors and/or inducers and P-gp inhibitors and/or inducers within 14 days (or 5 half-lives, whichever is longer) before the first administration and during the study;
  6. Participants with active infections requiring systemic anti-infective treatment within 1 week before the first administration;
  7. Participants who have received systemic or other , such as cyclophosphamide, azathioprine, methotrexate, and anti-tumor necrosis factor α agents, within 14 days before the first administration;
  8. Participants with other within 3 years before the first administration (except adequately treated basal cell/squamous cell carcinoma of the skin and carcinoma in situ of the cervix/breast);
  9. Participants who have not recovered from adverse events caused by previous antitumor treatment (recovered to Grade 1 or baseline level), except for alopecia, pigmentation of any grade, peripheral sensory neuropathy of Grade ≤2, and items already explicitly specified in the inclusion criteria, as well as other abnormalities that are clinically insignificant or considered to pose no risk by the investigator;
  10. Participants with a significant risk of thrombosis, such as deep vein thrombosis or pulmonary embolism within 3 months before screening, excluding venous thrombosis related to indwelling catheters or other procedures, superficial venous thrombosis, or thrombosis effectively treated with conventional anticoagulant therapy;
  11. Participants with nausea, vomiting, chronic gastrointestinal diseases including but not limited to active diverticulitis and symptomatic peptic ulcers, inability to swallow oral medications, or conditions such as previous extensive small bowel resection that, in the investigator's judgment, seriously affect gastrointestinal absorption;
  12. Participants with a history of or current retinal vein stenosis or occlusion (RVO), retinal pigment epithelial detachment (RPED), central retinal vein occlusion, glaucoma, or other ocular diseases that affect the assessment of ocular toxicity after administration of the product;
  13. Participants who have undergone major surgery within 4 weeks before the first administration or have not recovered from surgical complications;
  14. Participants who have received radiotherapy within 14 days before the first administration;
  15. Participants with symptomatic or unstable . Participants with previously treated brain metastases may participate in the study, provided that the following conditions are met: the lesions are stable (no evidence of progression on imaging examinations within 4 weeks before the first administration of study treatment, and any neurological symptoms are controlled and stable), there is no evidence of new or enlarging brain metastases, the investigator assesses the clinical condition as stable, and steroids have been discontinued for at least 14 days before the first administration of study treatment;
  16. Participants with any of the following cardiovascular diseases:

    • Symptomatic heart failure ( [NYHA] functional classification ≥ Class II);
    • \<50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan;
    • Poorly controlled hypertension repeatedly observed despite standard of care (SOC) treatment (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg);
    • Prolonged /QTc interval on during screening (QTcF >470 ms);
    • Acute coronary syndrome/acute myocardial infarction, unstable angina, percutaneous coronary intervention or coronary artery bypass grafting within 6 months before screening;
    • Cardiomyopathy of any etiology or valvular heart disease;
    • or stroke within 6 months before screening that, in the investigator's judgment, may affect this study;
    • Severe arrhythmias requiring clinical intervention;
    • Any other cardiovascular disease that, in the investigator's opinion, makes the participant unsuitable for participation in the study.
  17. Participants with uncontrolled pleural effusion, pericardial effusion, or ascites, or pleural effusion, pericardial effusion, or ascites requiring repeated drainage and medical intervention;
  18. Participants with any of the following viral infections at screening:

    • Active : HBV-DNA >500 IU/mL or 2000 copies/mL;
    • Active : positive HCV antibody and positive HCV-RNA;
    • (HIV) infection: positive antibody test;
    • Active syphilis: positive Treponema pallidum antibody (such as TPHA or FTA-ABS) and positive titer test (such as RPR or VDRL).
  19. Participants with a history of interstitial lung disease, drug-induced interstitial lung disease or radiation pneumonitis requiring steroid treatment, or clinically active interstitial lung disease;
  20. Participants with known drug abuse or psychiatric disorders that would interfere with compliance with study requirements;
  21. Participants who are pregnant or breastfeeding or intend to become pregnant during the study;
  22. Participants who, in the investigator's opinion, have other factors that may affect the study results or interfere with their participation throughout the study, including previous or existing physical conditions, treatments, or laboratory abnormalities, unwillingness to comply with the study procedures, restrictions, and requirements, or other circumstances that make them unsuitable for enrollment.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    FXS0260

    Participants will receive FXS0260, an oral small-molecule PKMYT1 inhibitor, at prespecified dose levels of 5, 20, 60, 120, or 180 mg twice daily (BID) during the dose-escalation phase (Phase Ia). Participants will receive a single oral dose during the single-dose administration period, followed by repeated dosing in subsequent treatment cycles. During the dose-expansion phase (Phase Ib), participants will receive FXS0260 at one or two recommended dose levels selected based on the results of Phase Ia. Treatment will continue until disease progression, unacceptable toxicity, death, withdrawal of informed consent, or other protocol-defined reasons for treatment discontinuation, whichever occurs first.

    Drug: FXS0260

Interventions

  • DrugFXS0260

    FXS0260 is an orally administered, selective small-molecule inhibitor of PKMYT1

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    DLTs will be assessed during the DLT observation period in Phase Ia. DLT-evaluable participants are defined as those who experience a DLT during the DLT observation period or receive at least 70% of the planned doses and complete the safety assessments.

    Time frame: From the first dose through Day 24 (Phase Ia only)

  2. Determination of MTD or MAD

    The MTD will be inferre based on DLT data and all safety data observed at all dose levels. The MTD is defined as the highest dose level at which no more than 30% of participants experience a DLT during the DLT observation period in the dose-escalation phase.If the MTD is not reached, the highest safe dose level will be defined as the MAD.

    Time frame: Up to 12 Months

  3. Incidence, Severity, and Relationship to Study Drug of Adverse Events (AEs)

    The incidence, severity, and relationship to FXS0260 of adverse events will be assessed. The severity of adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0.

    Time frame: From the first dose of FXS0260 through 28 days after the last dose.

  4. Determination of RP2D

    The RP2D of FXS0260 will be determined based on an integrated assessment of safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy data.

    Time frame: Through completion of the dose-escalation and dose-expansion assessments

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  2. The area under the plasma concentration-time curve from time 0 to the last measurable ocncentration (AUC0-t)of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  3. Time to reach maximum plasma concentration (Tmax) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  4. Elimination Half-life (T1/2) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  5. Apparent Clearance (CL/F) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  6. Apparent volume of distribution (Vz/F) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  7. Average concentration at steady state(Cavg,ss) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  8. Minimum observed concentration at steady state(Cmin,ss) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  9. Maximum observed concentration at steady state(Cmax,ss)of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  10. Elimination rate constant (λz) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  11. Apparent volume of distribution at steady state(Vss/F) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  12. Area under the plasma concentration time curve from time 0 to infinity(AUC0-∞)of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  13. Area under the plasma concentration-time curve over the dosing interval at steady state (AUCtau,ss) of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  14. Accumulation ratio(AR) based on Cmax of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  15. Accumulation ratio(AR) based on AUCtau, ss of FXS0260

    Pharmacokinetic parameter

    Time frame: From prodose on Day1 to 7 days after last dose of FXS0260

  16. Objective response rate, ORR

    Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

    Time frame: From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

  17. Progression Free Survival

    Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

    Time frame: From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

  18. Duration of Response (DoR)

    Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

    Time frame: From first dose of study drug until disease progression as defined by RECIST v1.1, initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

  19. Disease Control Rate (DCR)

    Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

    Time frame: From first dose of study drug until disease progression as defined by RECIST v1.1, initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

  20. Overall Suivaval (OS)

    Antitumor activity by evaluation of tumor response assessments based on RECIST 1.2

    Time frame: From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2026
First posted
Nov 12, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Dec 15, 2028
CompletionEst.
Dec 15, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07933666
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Dec 15, 2028 (estimated)
Completion
Dec 15, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Huijuan Yang
Contact
huijuanyang@hotmail.com
+86 21 64175590
Jian Zhang
Contact
Syner2000@163.com
+86 21 64175590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion